Takeda To Hunt For New CNS Therapeutics With Heptares' Technology
This article was originally published in The Pink Sheet Daily
Executive Summary
Making G-Protein coupled receptors in the CNS drugable is the aim of a research collaboration between Takeda and U.K. biotech, Heptares Therapeutics.
You may also be interested in...
Deals Of The Week: Sun/Dusa; Pfizer/Alliance For Lupus Research; Merck/Regenstrief Institute
Preclinical protein platform play Envoy got taken out by Takeda last week for up to $140 million. That magical “up to” typically hides a multitude of sins, but here that may not be the case.
Shire Exercises Option On Heptares' Preclinical Candidate In $190 Million Deal
The U.K.'s G-protein coupled receptor specialist, Heptares, could receive up to $190 million plus royalties from Shire as it concludes its first product out-licensing agreement.
U.K's Heptares Signs Up AstraZeneca In Latest GPCR-Focused Discovery Pact
AstraZeneca becomes the third Big Pharma in six weeks to sign up for U.K-based Heptares' GPCR stabilizing technology.